Nutriband Inc. NTRBW
Set alert
0.55 USD -1.18 -68.21%
As of Sep 30, 3:59 PM ET
0.3414 Day range 1.50
0.175 52-week range 2.99
- YTD
- -65.84%
- 1 year
- -62.84%
- Open
- 2.61
- Prev close
- 1.73
- Mkt cap
- 6.69M
- Vol
- 46.06K
- Avg vol
- 6.25K
- EPS
- -0.505
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3414
- High
- 1.50
- Forward P/E
- 0.00
- Beta
- 0.42
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.51
- 200-d avg
- 1.14
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.61
- EPS (TTM)
- -0.505
- Beta
- 0.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 2.02M
- Revenue growth
- -14.30%
- Free cash flow
- -1.55M
- Total cash
- 8.35M
- Total debt
- 527.92K
- Return on equity
- -60.41%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 1.51
- 200-day average
- 1.14
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
About Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nutriband.com
News
- Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274
- Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
- Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
- Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis
- Nutriband Inc. (NASDAQ:NTRBW) Short Interest Update
- Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
- Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
- Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
- Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
- Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
Your note
Sign in to keep a note on NTRBW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Citadel Advisors Llc | 15.55% | 116,591 | 221.52K | Sep 29, 2024 |
| Virtu Financial LLC | 1.49% | 11,154 | 21.19K | Sep 29, 2024 |
| Clear Street LLC | 0.48% | 3,608 | 6.86K | Sep 29, 2024 |
| UBS Group AG | 0.06% | 415 | 788 | Sep 29, 2024 |